Product Pipeline: Heart Failure
Coronary artery disease, myocardial infarction, cardiomyopathy, valvular disorders, and high blood pressure are often precursors to heart failure, but it is difficult to predict if and when heart failure symptoms will occur and how rapidly they will progress.
Although heart failure is a serious condition with no specific cure, patients can return to reasonable daily activity levels if they are directed to intensive heart failure treatment programs in a timely manner. Currently available therapies include medications, implanted devices, and procedures used to manage the underlying disease and symptoms such as shortness of breath, fluid accumulation, and arrhythmias. However, it is often difficult to determine which therapy or combination of interventions will provide the best results for an individual patient.
At CardioDx we began our work in this area by studying patient response to beta blockers based on genotypes of beta adrenergic receptors.1 We continue to explore how we can provide physicians with informative, actionable tests to enable them to individualize the complex approaches to the assessment, monitoring and care of their heart failure patients. Currently, CardioDx has no clinical studies underway for heart failure; we hope to initiate further clinical studies in the future.
- Sehnert AJ, Daniels SE, Elashoff M, et al. Lack of Association Between Adrenergic Receptor Genotypes and Survival in Heart Failure Patients Treated with Carvedilol or Metoprolol. J Am Coll Cardiol. 2008;52(8):644-51.